S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Saudi Arabia is slashing oil supply. It could mean higher gas prices for US drivers
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
Here's something only a handful of people know (Ad)
Greek authorities rescue 91 migrants from river islet on border with Turkey
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
Here's something only a handful of people know (Ad)
Saudi Arabia to reduce oil output by 1 million barrels per day, while rest of OPEC+ extends previous cuts through 2024
US, UK navies say they respond to distress call as Iran's Revolutionary Guard 'harassed' ship
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Saudi Arabia is slashing oil supply. It could mean higher gas prices for US drivers
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
Here's something only a handful of people know (Ad)
Greek authorities rescue 91 migrants from river islet on border with Turkey
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
Here's something only a handful of people know (Ad)
Saudi Arabia to reduce oil output by 1 million barrels per day, while rest of OPEC+ extends previous cuts through 2024
US, UK navies say they respond to distress call as Iran's Revolutionary Guard 'harassed' ship
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Saudi Arabia is slashing oil supply. It could mean higher gas prices for US drivers
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
Here's something only a handful of people know (Ad)
Greek authorities rescue 91 migrants from river islet on border with Turkey
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
Here's something only a handful of people know (Ad)
Saudi Arabia to reduce oil output by 1 million barrels per day, while rest of OPEC+ extends previous cuts through 2024
US, UK navies say they respond to distress call as Iran's Revolutionary Guard 'harassed' ship
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Saudi Arabia is slashing oil supply. It could mean higher gas prices for US drivers
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
Here's something only a handful of people know (Ad)
Greek authorities rescue 91 migrants from river islet on border with Turkey
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
Here's something only a handful of people know (Ad)
Saudi Arabia to reduce oil output by 1 million barrels per day, while rest of OPEC+ extends previous cuts through 2024
US, UK navies say they respond to distress call as Iran's Revolutionary Guard 'harassed' ship
NASDAQ:ATHA

Athira Pharma (ATHA) Stock Forecast, Price & News

$3.02
+0.27 (+9.82%)
(As of 06/2/2023 ET)
Compare
Today's Range
$2.75
$3.02
50-Day Range
$2.26
$3.04
52-Week Range
$2.22
$9.92
Volume
326,682 shs
Average Volume
151,258 shs
Market Capitalization
$114.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

Athira Pharma MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
231.1% Upside
$10.00 Price Target
Short Interest
Healthy
5.81% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.89mentions of Athira Pharma in the last 14 days
Based on 4 Articles This Week
Insider Trading
Acquiring Shares
$12,000 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.34) to ($3.62) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.31 out of 5 stars

Medical Sector

237th out of 980 stocks

Biological Products, Except Diagnostic Industry

32nd out of 163 stocks


ATHA stock logo

About Athira Pharma (NASDAQ:ATHA) Stock

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.

Receive ATHA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Athira Pharma and its competitors with MarketBeat's FREE daily newsletter.

ATHA Stock News Headlines

Athira Pharma, Inc. (NASDAQ:ATHA) Short Interest Update
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Stifel Nicolaus Remains a Hold on Athira Pharma (ATHA)
Athira Pharma Names Andrew Gengos CFO - Quick Facts
Athira Pharma gets new finance chief
Athira Pharma (ATHA) Receives a Hold from Stifel Nicolaus
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty
A unique type of investment could help you make more money than you will need for the rest of your life. It’s what we call the “Amazon secret royalty program.” It’s an income stream that allows you to collect $1,000s… $10,000s… or more every year! Learn how to collect your first payout before June 13th.
JMP Securities Keeps Their Buy Rating on Athira Pharma (ATHA)
BTIG Sticks to Their Buy Rating for Athira Pharma (ATHA)
Athira Pharma (ATHA) to Release Earnings on Wednesday
See More Headlines

ATHA Price History

ATHA Company Calendar

Last Earnings
3/23/2023
Today
6/04/2023
Next Earnings (Estimated)
8/21/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ATHA
Fax
N/A
Employees
34
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.00
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+231.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

Net Income
$-95,640,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.56 per share

Miscellaneous

Free Float
32,296,000
Market Cap
$114.61 million
Optionable
Not Optionable
Beta
2.82

Key Executives

  • Dr. Mark J. Litton M.B.A. (Age 54)
    MBA, Ph.D., Pres, CEO & Director
    Comp: $726.32k
  • Ms. Rachel P. Lenington M.B.A.
    Chief Operating Officer
  • Mr. Mark F. Worthington J.D.
    Gen. Counsel & Corp. Sec.
  • Ms. Glenna K. Mileson (Age 63)
    Chief Financial Officer
  • Mr. Robert Renninger
    Director of Accounting & Reporting
  • Ms. Julie Rathbun
    Head of Investor Relations
  • Dr. Kevin Church Ph.D. (Age 37)
    Exec. VP of Research













ATHA Stock - Frequently Asked Questions

Should I buy or sell Athira Pharma stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Athira Pharma in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ATHA shares.
View ATHA analyst ratings
or view top-rated stocks.

What is Athira Pharma's stock price forecast for 2023?

5 equities research analysts have issued 12-month price targets for Athira Pharma's stock. Their ATHA share price forecasts range from $5.00 to $20.00. On average, they expect the company's stock price to reach $10.00 in the next year. This suggests a possible upside of 231.1% from the stock's current price.
View analysts price targets for ATHA
or view top-rated stocks among Wall Street analysts.

How have ATHA shares performed in 2023?

Athira Pharma's stock was trading at $3.17 at the start of the year. Since then, ATHA shares have decreased by 4.7% and is now trading at $3.02.
View the best growth stocks for 2023 here
.

Are investors shorting Athira Pharma?

Athira Pharma saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 2,050,000 shares, a decrease of 5.5% from the April 30th total of 2,170,000 shares. Based on an average trading volume of 214,500 shares, the short-interest ratio is currently 9.6 days. Approximately 5.8% of the company's stock are sold short.
View Athira Pharma's Short Interest
.

When is Athira Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our ATHA earnings forecast
.

How were Athira Pharma's earnings last quarter?

Athira Pharma, Inc. (NASDAQ:ATHA) posted its quarterly earnings results on Thursday, March, 23rd. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.70) by $0.09.

What ETFs hold Athira Pharma's stock?

ETFs with the largest weight of Athira Pharma (NASDAQ:ATHA) stock in their portfolio include Simplify Propel Opportunities ETF (SURI).iShares Neuroscience and Healthcare ETF (IBRN).

What other stocks do shareholders of Athira Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Athira Pharma investors own include GW Pharmaceuticals (GWPH), Intel (INTC), Lumentum (LITE), NIO (NIO), NVIDIA (NVDA), Boeing (BA), Alibaba Group (BABA), Beyond Meat (BYND), Delta Air Lines (DAL) and Extreme Networks (EXTR).

When did Athira Pharma IPO?

(ATHA) raised $160 million in an initial public offering (IPO) on Friday, September 18th 2020. The company issued 10,000,000 shares at $15.00-$17.00 per share. Goldman Sachs, Jefferies and Stifel acted as the underwriters for the IPO and JMP Securities was co-manager.

What is Athira Pharma's stock symbol?

Athira Pharma trades on the NASDAQ under the ticker symbol "ATHA."

Who are Athira Pharma's major shareholders?

Athira Pharma's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Baker BROS. Advisors LP (6.19%), BlackRock Inc. (5.99%), BML Capital Management LLC (4.92%), Simplify Asset Management Inc. (3.66%), Geode Capital Management LLC (1.67%) and Two Sigma Advisers LP (1.30%). Insiders that own company stock include Glenna Mileson, Hans Moebius, James A Johnson, Joseph Edelman, Kelly A Romano, Mark James Litton, Mark Worthington, Perceptive Advisors Llc and Rachel Lenington.
View institutional ownership trends
.

How do I buy shares of Athira Pharma?

Shares of ATHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Athira Pharma's stock price today?

One share of ATHA stock can currently be purchased for approximately $3.02.

How much money does Athira Pharma make?

Athira Pharma (NASDAQ:ATHA) has a market capitalization of $114.61 million. The company earns $-95,640,000.00 in net income (profit) each year or ($2.70) on an earnings per share basis.

How can I contact Athira Pharma?

The official website for the company is athira.com. The company can be reached via phone at 425-620-8501 or via email at ir@athira.com.

This page (NASDAQ:ATHA) was last updated on 6/4/2023 by MarketBeat.com Staff

My Account -